Showing 759 news articles about Hepatitis C treatment

Filters Content type: Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

New & experimental hepatitis C treatment

Who will win the hepatitis C market?

Editor's pick
Seeking Alpha
15 March 2011
Hepatitis C treatment

FDA Panel To Review Merck, Vertex Hepatitis Drugs In Late April

Editor's pick
Wall Street Journal
15 March 2011
New & experimental hepatitis C treatment

The Hepatitis C Pipeline Report

Editor's pick
Treatment Action Group
9 March 2011
Hepatitis C treatment

Pharmasset Hep C Data Wows Investors

Editor's pick
The Street
9 March 2011
Hepatitis C treatment

Lack of health insurance limits hepatitis C patients' access to latest antiviral therapy

Editor's pick
Eurekalert Inf Dis
24 February 2011
Hepatitis C treatment

Medivir Announces Positive Phase 2b 48-week (SVR24) Interim Results of TMC435 in Treatment-Naive Patients Chronically Infected With Genotype-1 Hepatitis C Virus

Editor's pick
PR Newswire
22 February 2011
Hepatitis C treatment

Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 In Adults With Chronic Genotype 1 HCV

Editor's pick
Medical News Today
22 February 2011
Pharmaceutical industry

Idenix drops after FDA loosens one hold but slaps on another

Editor's pick
Fierce Biotech
10 February 2011
Hepatitis C symptoms & diagnosis

Vertex urges CDC to recommend hep C screening, to nudge `second tsunami` of patients

Editor's pick
EATG
3 February 2011
Hepatitis C treatment

Hep C Treatment Telaprevir Gets Fast-Tracked FDA Review

Editor's pick
AIDSMeds
21 January 2011
Hepatitis C treatment

Copy of Hep C Treatment Telaprevir Gets Fast-Tracked FDA Review

Editor's pick
Kaiser Daily Global Health Policy Report
21 January 2011
People with limited treatment options

Manufacturer Recalls Alcohol Swab Products Packaged with Fuzeon, Other Meds

Editor's pick
AIDSmeds
20 January 2011
Hepatitis C symptoms & diagnosis

New drugs take aim at hepatitis C, spur debate on whether to test baby boomers

Editor's pick
Canadian Press
18 January 2011
Hepatitis C treatment

Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C

Editor's pick
Market Wire
10 January 2011
Hepatitis C treatment

Bristol-Myers Squibb and Pharmasset Enter into a Clinical Collaboration Agreement for Proof of Concept Combination Study in Patients Chronically Infected with Hepatitis C

Editor's pick
Business Wire
10 January 2011
Hepatitis C treatment

Merck Beats Vertex to FDA Hep C Filing

Editor's pick
The Street
7 January 2011
Hepatitis C treatment

Pharmasset Reports Positive Results from its HCV Clinical Programs

Editor's pick
Pharmasset
6 January 2011
Hepatitis C treatment

Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients

Editor's pick
PR Newswire
5 January 2011
Hepatitis C treatment

Hepatitis Experts Create Roadmap for Accelerating the Development of Targeted Therapies for Hepatitis C Virus

Editor's pick
Forum for Collaborative HIV Research
15 December 2010
Hepatitis C treatment

Medivir AB reports positive interim data on Phase 2b ASPIRE study for hepatitis C

Editor's pick
Medical News Today
18 November 2010
Hepatitis C treatment

Early analysis finds good outcomes with once-daily dosing of HCV protease inhibitor TMC435

Editor's pick
HIVandhepatitis.com
8 November 2010
Hepatitis C treatment

From podium to practice: Updates in HCV treatment

Editor's pick
Clinical Care Options (registration required)
8 November 2010
Clinical trials

Hepatitis C researcher arrested on insider trading charges

Editor's pick
New York Times
3 November 2010
Hepatitis C treatment

AASLD: Anti-HCV drug boosts response rates

Editor's pick
MedPage Today
3 November 2010